AntiRadical Therapeutics (ART) is developing novel drugs based on catalytic nitric oxide (CNO) technology chemically linked to macromolecules (e.g., hemoglobin) for the treatment of stroke, cancer, trauma and Alzheimer’s Disease. The lead drug in our pipleline is a polynitroxylated pegylated carbon monoxy hemoglobin (PNPH aka SanFlow).

Nitric oxide (NO) is the key regulator of blood flow, oxygen delivery, antioxidant, anti-inflammatory and immune response activities in central and peripheral organs at the cellular and vascular level, and across the blood brain barrier.

The efficacy of this drug activity has been published by leading experts in their fields with funding from State, Federal and private investments.

ART will have five 17 years of global patent protections on compositions and methods of use of this catalytic nitric oxide drug.

Confidential information of the pending patent applications will be disclosed under CDA with interested parties.